Immodulon’s vision is to establish IMM-101 as backbone immunotherapy in combination with existing and future standards of care. Our clinical trials programme is designed with this in mind. Clinical studies to date have indicated that IMM‑101 is well tolerated and encouraging increases in overall survival for patients with advanced melanoma and pancreatic cancer have been demonstrated.